Home  >  Products  >  SLC25A20 (solute carrier family 25 (carnitine/acylcarnitine translocase) member 20) Blocking Peptide (the C terminal of protein) (100ug)
SLC25A20 (solute carrier family 25 (carnitine/acylcarnitine translocase) member 20) Blocking Peptide (the C terminal of protein) (100ug)

SLC25A20 (solute carrier family 25 (carnitine/acylcarnitine translocase) member 20) Blocking Peptide (the C terminal of protein) (100ug)


Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-SLC25A20 antibody (Catalogue #: ARP43748_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Presku: AAP43748
Size: 100 ug
Weight: 33kDa
Gene: 788
Format: Lyophilized powder
Target: SLC25A20 is one of several closely related mitochondrial-membrane carrier proteins that shuttle substrates between cytosol and the intramitochondrial matrix space.It mediates the transport of acylcarnitines into mitochondrial matrix for their oxidation by the mitochondrial fatty acid-oxidation pathway. Mutations in this gene are associated with carnitine-acylcarnitine translocase deficiency, which can cause a variety of pathological conditions such as hypoglycemia, cardiac arrest, hepatomegaly, hepatic dysfunction and muscle weakness, and is usually lethal in new born and infants.This gene product is one of several closely related mitochondrial-membrane carrier proteins that shuttle substrates between cytosol and the intramitochondrial matrix space. This protein mediates the transport of acylcarnitines into mitochondrial matrix for their oxidation by the mitochondrial fatty acid-oxidation pathway. Mutations in this gene are associated with carnitine-acylcarnitine translocase deficiency, which can cause a variety of pathological conditions such as hypoglycemia, cardiac arrest, hepatomegaly, hepatic dysfunction and muscle weakness, and is usually lethal in new born and infants. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.
Alternative names: CAC; CACT